Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy

The U.S. FDA granted Fast Track designation to Lu AH69593, an oral orexin-2 receptor agonist, for the treatment of narcolepsy. The program targets orexin-2 signaling, a pathway central to wakefulness and sleep-wake regulation. Fast Track status is a positive regulatory milestone that can accelerate development timelines and improve prospects for clinical progress.

Analysis

The U.S. FDA granted Fast Track designation to Lu AH69593, an oral orexin-2 receptor agonist, for the treatment of narcolepsy. The program targets orexin-2 signaling, a pathway central to wakefulness and sleep-wake regulation. Fast Track status is a positive regulatory milestone that can accelerate development timelines and improve prospects for clinical progress.